Skip to main content

Biodesix Inc

BDSX
Exchange
Nasdaq
Industry
Services-Medical Laboratories
SEC CIK
0001439725

In the last 90 days, Biodesix Inc insiders filed 2 open-market purchases and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Biodesix Inc changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of BDSX: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders46237−7
Shares4.18M29.7K3.72M−425.4K (−10.3%)
Value$7.06M$51.0K$5.99M−$1.02M (−14.5%)

2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (12)

Institutions that held Biodesix Inc at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to BDSX in Q2 2022
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC56,600$93.0K0.00%
Allworth Financial LP55,853$92.0K0.00%
Ergoteles LLC22,223$36.0K0.00%
Qube Research & Technologies Ltd15,671$26.0K0.00%
CPWM, LLC15,497$25.0K0.00%
Two Sigma Securities, LLC13,169$22.0K0.00%
Goldman Sachs Group Inc10,850$18.0K0.00%
Verition Fund Management LLC10,973$18.0K0.00%
HRT Financial LP11,005$18.0K0.00%
Equitec Proprietary Markets, LLC6,900$11.0K0.01%
Credit Suisse AG8$00.00%
Ellevest, Inc.139$00.00%

Sold out (19)

Institutions that held Biodesix Inc at the end of Q1 2022 and filed for Q2 2022 without it.

Not filed for Q2 2022 yet (2)

Institutions that held Biodesix Inc at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding BDSX in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Parametric Portfolio Associates LLC27,644$47.0K
Amalgamated Financial Corp.2,101$4.00K